Puranik AD, Dev ID, Yadav S, Rangarajan V, et al. PReCedeNT trial: Phase III randomized-controlled trial of Lutetium - 177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) plus Chemotherapy versus PRRT alone in FDG-avid, Well-differentiated Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) BMC Cancer 2025;25:1659.
PMID: 41152774